TITLE:
New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects

CONDITION:
Human Immunodeficiency Virus I Infection

INTERVENTION:
abacavir/lamivudine

SUMMARY:

      A 48-week study to investigate the safety and effectiveness of a new compact formulation of
      two already FDA-approved anti-HIV drugs in subjects who have already been receiving
      treatment for their HIV infection.
    

DETAILED DESCRIPTION:

      A phase III, randomized, open-label, parallel, multicenter study to evaluate treatment with
      fixed-dose combination of abacavir/lamivudine (600mg/300mg) once-daily versus abacavir
      (300mg) twice-daily and lamivudine (300mg) once-daily in combination with tenofovir
      once-daily and a new PI or NNRTI for 48 weeks in ART-experienced HIV-1 infected patients.
    

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Antiretroviral therapy (ART) experienced and currently receiving a stable regimen
             containing 3 nucleoside reverse transcriptase inhibitors (NRTIs), or 2 NRTIs plus a
             protease inhibitor (PI) or non-nucleoside reverse transcriptase inhibitors (NNRTI)
             for at least 3 months (there should be no significant ART modifications for at least
             3 months and no ART change anticipated between Screening and initiation of the study
             therapy).

          -  Patients must be naive to tenofovir.

          -  HIV-1 RNA level > 1000 copies/ml on at least one occasion within 21 days of study
             entry.

          -  A CD4 cell count > 50 cells/mm3.

          -  Specified viral genotypes.

        Exclusion Criteria:

          -  Pregnant or breast-feeding women.

          -  Has an active diagnosis of AIDS.

          -  Additional qualifying criteria to be determined by the physician.
      
